Vibeke Strand
Rheumatology · Portola Valley, CANPI 1194882753
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $545,270 of the $700,525 with a category attached, or 77.8%. It is spread thinly across 37 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2019 at $206,173 and has fallen 75.4% since, to $50,800 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $1663.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$142K
- Amgen$80K
- E.r. Squibb & Sons, L.L.C.$60K
- Boehringer Ingelheim$58K
- Astrazeneca UK Limited$48K
- Novartis$46K
- plus $267K from 31 others
Across 87 payments — averaging $1622.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$81K
- Novartis$14K
- Pfizer$13K
- Bioventus LLC$9K
- Endo Pharmaceuticals Inc.$8K
- Amgen$6K
- plus $11K from 4 others
What the payments were for
- Consulting fees$545,27078%
- Speaking & faculty fees$112,57816%
- Grants$7,7631%
- Travel & lodging$27,9734%
- Food & beverage$6,9411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $142,039 |
| Amgen(2 entities) | 58 | $80,096 |
| E.r. Squibb & Sons, L.L.C. | 56 | $60,473 |
| Boehringer Ingelheim | 20 | $57,738 |
| Astrazeneca UK Limited | 19 | $47,563 |
| Novartis | 30 | $45,503 |
| Pfizer | 18 | $37,873 |
| AstraZeneca | 14 | $22,353 |
| Whitehall International Inc | 4 | $21,743 |
| Bioventus LLC | 8 | $21,613 |
| Pacira Therapeutics, Inc. | 8 | $19,079 |
| Novartis Pharma AG | 4 | $18,053 |
| EMD Serono, Inc. | 5 | $17,639 |
| Gilead | 4 | $14,273 |
| Bayer | 18 | $13,397 |
| Swedish Orphan Biovitrum AB | 4 | $13,308 |
| Sanofi-aventis U.S. LLC | 11 | $11,577 |
| Regeneron Healthcare Solutions, Inc. | 15 | $10,345 |
| Sanofi US Services Inc. | 2 | $8,910 |
| GSK | 3 | $5,411 |
| Pacira Pharmaceuticals Incorporated | 1 | $5,040 |
| Sandoz | 3 | $4,886 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,763 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $3,300 |
| Eli Lilly | 4 | $3,133 |
| Shionogi Inc | 1 | $2,800 |
| Samsung Bioepis Co., Ltd. | 3 | $2,610 |
| Sobi, Inc | 5 | $2,279 |
| Sanofi | 3 | $1,728 |
| Lilly USA, LLC | 5 | $284 |
| UCB, Inc. | 3 | $191 |
| Janssen Scientific Affairs, LLC | 3 | $158 |
| Aurinia Pharma U.S., Inc. | 1 | $117 |
| Bristol Myers Squibb | 2 | $109 |
| Regeneron | 2 | $96 |
| Genentech, Inc. | 1 | $31 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$48,866
- SAPHNELO$45,013
- XELJANZ$41,695
- KRYSTEXXA$34,812
- KEVZARA$32,361
- Skyrizi$27,288
- Tavneos$23,209
- Zilretta$19,075
- Sprifermin$17,375
- Essure$13,184
- INFLECTRA$12,513
- Rinvoq$10,478
- CEC_COSENTYX_IMMUNOLOGY$9,735
- Enbrel$6,026
- Sotyktu$5,999
- ERELZI$4,886
- COSENTYX_COSENTYX_DERMATOLOGY$4,543
- Humira$4,500
- DIOVAN$1,019
- SB35$700
How this compares
$700,525 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Portola Valley
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.